While Small Molecule structures continue to be a cornerstone of Pharmaceutical development, CordenPharma brings extensive experience and infrastructure to this arena.
We combine considerable R&D development resources with a wide range of manufacturing capacity to assist with your project at any stage of clinical development and projected commercial scale of supply.
Our extensive reactor capacity of over 1,200,000 L total volumetric capacity spread over ~150 individual reactors ranging from 20 L to 28,000 L enable the organization to deliver your product at any scale to support either your development requirements or commercial supply needs.
CordenPharma brings over 200 combined years of experience in the Small Molecule development and manufacturing market, where we have considerable experience with a repertoire of chemical reactions and transformations, including but not limited to:
- >> Hydrogenations
- >> Oxidations
- >> Cryogenics
- >> Friedal-Crafts
- >> Organometallics
- >> Amination
- >> Cyanation
- >> Carbonylation
- >> Diels-Alder
- >> Acylation
- >> Phosphorylation
- >> Bio-Catalysis
- >> Chiral Synthesis
We are experts in natural product isolation via extraction from biomass to produce either intermediates for further elaboration or the final Drug Substance itself.
With our extensive infrastructure we can support your program with the manufacture of the final Drug Substance Active Pharmaceutical Ingredients (APIs) or Advanced Intermediates manufactured under GMP. As a Drug Product manufacturer, we can also forward integrate your program by taking your Drug Substance and converting it into tablets, capsules, sachet or non-sterile liquid formulations, as well as provide full secondary packaging capabilities, including serialization and aggregation services.
CordenPharma’s ability to develop and manufacture Active Pharmaceutical Ingredients (APIs), Finished Dosage and Packaging in our network of facilities allows clients full access to integrated services resulting in a simplified supply chain, reduced risk and cost associated with technology transfers, and ultimately faster production and delivery timelines.